Kenneth Thress is a senior director in translational medicine focusing on antibody-drug conjugates at AstraZeneca, where they have contributed to oncology drug development for 22 years. Kenneth has led various projects, including those related to osimertinib and gefitinib, while executing translational science strategies to enhance clinical progression. Their career includes significant international assignments and leadership roles in companies such as TESARO and Novartis. Kenneth holds a BS in Biology from Trinity College-Hartford and a PhD in Cancer Biology from Duke University.
Location
Waltham, United States
Links
This person is not in any teams
This person is not in any offices